Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer

Authors

Andrew F. Voter, Advocate Aurora HealthFollow
Rudolf A. Werner, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kenneth J. Pienta, The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael A. Gorin, Urology Associates and UPMC Western Maryland, Cumberland, MD, USA.
Martin G. Pomper, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Lilja B. Solnes, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Steven P. Rowe, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Recommended Citation

Voter AF, Werner RA, Pienta KJ, et al. Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer . Expert Rev Anticancer Ther. 2022;22(7):681-694. doi:10.1080/14737140.2022.2081155

Affiliations

Aurora St. Luke's Medical Center

Abstract

Introduction: Accurate imaging is essential for staging prostate cancer and guiding management decisions. Conventional imaging modalities are hampered by a limited sensitivity for metastatic disease. Nearly all prostate cancers express prostate-specific membrane antigen (PSMA) and ¹⁸F-DCFPyL (piflufolastat F 18) is a new FDA-approved positron emission tomography (PET) agent that targets PSMA for improved staging of prostate cancer.

Areas covered: This article provides an overview of PSMA, the mechanism of action of ¹⁸F-DCFPyL, and compares the performance of ¹⁸F-DCFPyL to conventional prostate imaging modalities. Current prostate cancer imaging guidelines are reviewed, as well as what changes can be expected in the future with increased access to PSMA-PET.

Expert opinion: The OSPREY and CONDOR clinical trials have demonstrated the superiority of ¹⁸F-DCFPyL over conventional imaging modalities for the staging and restaging of prostate cancer. The remarkable diagnostic accuracy of PSMA-PET is reshaping prostate cancer imaging and the modularity of these agents hint at exciting new diagnostic and therapeutic opportunities that have the potential to improve the care of patients with prostate cancer as a whole. .

Type

Article

PubMed ID

35603510